The criminal Maduro regime issued bogus warrants to arrest members of the Venezuelan opposition, including several campaign staffers working for opposition leader María Corina Machado, who won the opposition’s primary election earlier this year. Last night, Roberto...
El senador estadounidense Marco Rubio (R-FL) habló con Ninoska Pérez en La Poderosa 670 AM, sobre los grupos en EE.UU. que apoyan la masacre que lidera Hamás contra Israel, sobre los reclamos para un cese de fuego, sobre el arresto de Manuel Rocha y más. Una...
Yes, We Should Restrict U.S. Investment in China U.S. Senator Marco Rubio (R-FL) December 7, 2023 National Review [A] recent investigation reveals that U.S. firm BlackRock is funneling the assets of millions of unwitting Americans into Chinese companies directly...
Stop foreign adversaries like China from corrupting American schools U.S. Senator Marco Rubio (R-FL) December 7, 2023 New York Post Before lawmakers headed home for turkey and cranberry sauce, the bipartisan, bicameral US-China Economic and Security Review Commission...
U.S. Senators Marco Rubio (R-FL) and Rick Scott (R-FL) introduced a resolution honoring the fourth anniversary of the terrorist attack at Naval Air Station (NAS) Pensacola. “Four years ago, three of our brave service members tragically lost their lives in a senseless...
U.S. Senator Marco Rubio (R-FL) joined The Business Briefing to discuss his call for President Biden to ban U.S.-China travel, the Putting American Autoworkers First Act, Florida’s economic growth, and more. See below for highlights and listen to the full interview...
Rubio, Warren Introduce Bill to Address U.S. Overreliance on Foreign Pharmaceuticals
Washington, D.C. — U.S. Senators Marco Rubio (R-FL) and Elizabeth Warren (D-MA) introduced the Strengthening Supply Chains for Servicemembers and Security Act to address the national security risk posed by the United States’ reliance on foreign entities for pharmaceuticals. The legislation follows a September 2021 report from the Department of Defense (DoD) Office of Inspector General (OIG) that confirmed the DoD is over-reliant on foreign made pharmaceuticals without sufficient strategies to address domestic supply chain dysfunction. The Senators successfully secured language in the National Defense Authorization Act for Fiscal Year 2021 to require an industrial capacity vulnerability study of the DoD’s dependence on foreign-made pharmaceuticals.
“The report from the Department of Defense Office of Inspector General only confirms what was made glaringly obvious during the COVID-19 pandemic: the United States remains dangerously reliant on foreign nations for its pharmaceuticals,” Rubio said. “It is unacceptable that we do not currently have a plan in place to address these supply chain issues. I’m proud to introduce this legislation to ensure that the DoD is able to reduce its reliance on nations like China for its critical pharmaceutical needs.”
“The COVID-19 pandemic has demonstrated the vulnerability of our nation’s supply chains, including of pharmaceutical products,” Warren said. “This poses a risk not only to public health but to our national security. I’m glad to lead this bill with Senator Rubio to ensure DoD takes steps to reduce its reliance on pharmaceuticals manufactured abroad and to strengthen its supply chains,” said Senator Warren.
The Strengthening Supply Chains for Servicemembers and Security Act would codify the six recommendations included in the DoD OIG report to address supply chain weaknesses:
Recommendation that the Under Secretary of Defense for Acquisition and Sustainment:
- Develop and issue implementing guidance for DoD supply chain risk management for DoD material, which includes pharmaceuticals.
- Pursue Federal legislation requiring pharmaceutical manufacturers to include APIs and final drug product country of origin information of the pharmaceuticals’ lot on the pharmaceuticals’ packaging. Specifically, the legislation would require a further review of information gaps to address reliance concerns.
Recommendation that the Director of the Defense Health Agency:
- Develop and publish implementing guidance for supply chain risk management specifically for pharmaceuticals.
- Create a chartered work group to assess risks to the pharmaceutical supply chain, identify the pharmaceuticals most critical to beneficiary care at DoD MTFs, and establish policy for allocating scarce pharmaceutical resources in case of a supply disruption.
Recommendation that the Director of the Defense Logistics Agency modify DLA Instructions 5025.03 and 3110.01 to:
- Require DLA Troop Support to coordinate annually with Military Service customers to conduct responsiveness testing of the DLA’s contingency contracts for pharmaceuticals.
- Include the contract responsiveness testing results, as reported by the Military Service customers, in the Warstopper Program annual reports.